Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

of the other agents in the CHOP regimen was standard; cyclophosphamide at 750 mg/m2 IV, vincristine at 1.4 mg/m2 IV on day one, and prednisone or prednisolone 100 mg orally on days one through five.

PIX-R TRIAL™ Design

The PIX-R trial is designed to be a randomized, multicenter study comparing pixantrone plus rituximab to gemcitabine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma ("DLBCL") or DLBCL transformed from follicular lymphoma who have received one to three prior lines of therapy, including CHOP-R or an equivalent regimen. The patients to be enrolled in the PIX-R trial cannot be eligible for high-dose (myeloablative) chemotherapy and stem cell transplant, but patients who relapse after such a procedure are eligible. The co-primary endpoints for the PIX-R trial are progression free survival and OS with secondary endpoints including ORR (ORR equals complete responses plus partial responses), complete response rate and safety.  CTI is targeting to enroll 350 patients over 18 months in the PIX-R trial.

The PIX-R trial may serve as either a post-marketing commitment trial or as a follow-on pivotal trial depending on the outcome of a formal appeal that CTI submitted to the U.S. Food & Drug Administration's (the "FDA") Office of New Drugs in the FDA's Center for Drug Evaluation and Research in December 2010 regarding its 2010 decision about CTI's new drug application (the "NDA") for pixantrone. The NDA for pixantrone was based on the results of the PIX 301 trial, a randomized trial comparing pixantrone as monotherapy to a choice of standard single-agent chemotherapy in relapsed/refractory aggressive NHLpatients. CTI expects a decision regarding its appeal in the second quarter of 2011.

EMA

In Europe, the Marketing Authorization Application (the "MAA") for pixantrone as monotherapy for patients with relapsed or refractory aggressive NHL is currently under review b
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will increase to a value of over ... by expansion in the large direct energy device market. ... increasingly adopted due to the advantages they offer and ... findings from Decision Resources Group,s coverage of the U.S. ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... University Medical Pharmaceuticals, which specializes in developing and distributing ... to the mass market, announced today that it has ... , Mr. Ten brings 28 years of ... luxury and consumer packaged goods industry. At University ...
... Inc., a company leading the scientific research of neurogenesis ... identify novel pathways for the treatment of central nervous ... Scolnick from the Broad Institute of MIT and Harvard ... to its scientific advisory board. The appointees join BrainCells, ...
Cached Medicine Technology:University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales 2University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales 3BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman 2BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman 3
(Date:12/20/2014)... 20, 2014 Angeldress.co.uk, the distinguished wedding ... for worldwide dress fans. The company has recently updated ... information. For the holiday season, Angeldress Blog ... wedding apparel. , Angeldress.co.uk prides itself in offering a ... of service. All the company’s outfits are very carefully ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 The ... has caused quite a stir, not only in Hollywood, but ... on December 18th , the ripples of that attack are ... executives’ very jobs at risk. But they are not ... correspondences exposed could be in for some embarrassing times ahead, ...
(Date:12/20/2014)... December 20, 2014 Xarelto bleeding ... suffered uncontrollable bleeding and other serious side effects ... District of Louisiana for coordinated pretrial proceedings, Wright & ... Litigation (JPML) issued an order Friday to transfer 21 ... in 22 federal courts to the Louisiana district court ...
(Date:12/20/2014)... Today, Balfleet.com, one of the most outstanding dressmakers in ... on its Mother of the Bride Dresses ... bride dresses from Balfleet.com feature gorgeous looks and delicate ... pride in providing high quality dresses to its clients ... on our mother of the bride dresses, and we ...
(Date:12/19/2014)... 2014 Sweetdressy.com , a leading ... its newest selection of cheap prom dresses for ladies ... in the world and clients can buy these dresses ... prom dresses feature cool cuts and delicate craftsmanship, and ... the middle-end market. Discount shipping costs are available for ...
Breaking Medicine News(10 mins):Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2
... Actress and best-selling author,Jenny McCarthy has established herself ... autism cure and advocate for nutritional regimens to ... Health Trax(TM) (GHT) flagship,specialty probiotic product, ThreeLac(TM), into ... in her book Louder than,Words: A Mother,s Journey ...
... fails to ease symptoms, but old drug offers new hope ... step forward, one step back in the search for treatments ... the July 19 issue of The Lancet , an ... a second report, a once-promising vaccine failed to prevent the ...
... Women Veterans, WASHINGTON, July 18 Dr. Paula ... Traumatic,Stress Disorder (PTSD), received the 3rd annual Ladies Home ... women veterans., "Dr. Schnurr,s contribution to veterans is ... who have borne the battle,",said Secretary of Veterans Affairs ...
... the earliest events occurring immediately upon infection with HIV-I ... the immune system earlier than was previously understood. According ... the window of opportunity for successful intervention may be ... after transmission, as researchers had previously believed. , Appearing ...
... patients develop resistance to chemotherapy drugs, sometimes abruptly, after ... working well to reduce tumors or hold them in ... result when this occurs is all too familiar: patients ... become resistant. , A team of researchers at Cold ...
... Proposed Acquisition to Strengthen Existing Therapeutic Focus Through ... Extending the ... 18 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP; "BMP Sunstone"; ... Co., Ltd. ("Sunstone") has signed a non-binding letter of,intent ...
Cached Medicine News:Health News:Global Health Trax Joins Fight Against Autism With Jenny McCarthy and Generation Rescue 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4Health News:HIV conquers immune system faster than previously realized 2Health News:HIV conquers immune system faster than previously realized 3Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 2Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 3Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 4Health News:BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co. 2Health News:BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co. 3
... Bledsoe Sport & Sport Max patellofemoral knee ... and/or collateral injuries. Patients with minor knee ... can benefit from added support to prevent ... designs to provide the right kind of ...
... Brace gives fracture treatment patients maximum support ... brace features the the Bledsoe Multi-Centric Hinge, ... and positively locks at any angle within ... slots, the Bledsoe Multi-Centric Hinge anatomically tracks ...
... The Bledsoe Revolution ... for speed fitting under ... frees the surgeon or ... time-consuming post-op fitting and ...
The Bledsoe Post-Op Knee Brace is designed to provide maximum protection without sacrificing comfort and quick, easy application....
Medicine Products: